Published in final edited form as:

Immunol Res. 2015 July ; 62(3): 341–356. doi:10.1007/s12026-015-8664-y.

Practical NK cell phenotyping and variability in healthy adults

Laura S. Angelo¹, Pinaki P. Banerjee¹, Linda Monaco-Shawver², Joshua B. Rosen³, George Makedonas¹, Lisa R. Forbes¹, Emily M. Mace¹, and Jordan S. Orange^{1,*}

¹Center for Human Immunobiology, Department of Allergy, Immunology and Rheumatology, The Feigin Center, Texas Children's Hospital, 1102 Bates Street, Suite 330, Houston, TX, USA 77030 and Baylor College of Medicine

²Children's Hospital of Philadelphia Research Institute, 3615 Civic Center Boulevard, Philadelphia, PA USA 19104

³Drexel University College of Medicine, 245 N. 15th Street, Philadelphia, PA USA 19102

Abstract

Human natural killer (NK) cells display a wide array of surface and intracellular markers that indicate various states of differentiation and/or levels of effector function. These NK cell subsets exist simultaneously in peripheral blood, and may vary amongst individuals. We examined variety amongst selected NK cell receptors expressed by NK cells from normal donors, as well as the distribution of select NK cell subsets and NK cell receptor expression over time in several individual donors. Peripheral blood mononuclear cells (PBMCs) were evaluated using flow cytometry via fluorochrome-conjugated antibodies against a number of NK cell receptors. Results were analyzed for both mean fluorescence intensity (MFI) and the percent positive cells for each receptor. CD56^{bright} and CD56^{dim} NK cell subsets were also considered separately, as was variation of receptor expression in NK cell subsets over time in selected individuals. Through this effort we provide ranges of NK cell surface receptor expression for a local adult population as well as provide insight into intra-individual variation.

Keywords

NK cells; immunological phenotype; primary immune deficiency; flow cytometry

1. Introduction

The detection and diagnosis of immunological diseases relies upon an ability to identify abnormalities in both the number and function of distinct populations of immune cells when compared to a reliable panel of healthy controls. The significance of maintaining a regionally relevant updated pool of age-matched normal donors for this purpose has been documented [1, 2]. Immune diseases, including Primary Immunodeficiency, typically contain quantitative and/or qualitative defects in immune cell subsets, which can include the NK cell compartment [3]. Identification of NK cell deficiencies relies on an accurate

Corresponding author: Laura S. Angelo, PhD, Center for Human Immunobiology, 1102 Bates Street, Suite FC330, Houston, TX, 77030, USA, laura.angelo@bcm.edu, phone: 832-824-2597, Fax: 832-835-1260.

assessment of the frequency of CD56⁺ CD3⁻ lymphocytes present in peripheral blood as well as the distribution of CD56^{bright} and CD56^{dim} NK cell subsets [3]. In addition, unique NK cell profiles may be indicative of particular immune deficiencies, such as that caused by GATA2 mutation [4].

NK cell maturation in both mice and humans begins in the bone marrow and is thought to proceed in secondary lymphoid tissues [5], [6]. Peripheral blood in the majority is represented by mature NK cells, but also contains immature and heterogeneous NK cell subsets. CD56^{bright} NK cells are thought to represent a less mature precursor of CD56^{dim} NK cells [6]. In addition to representing particular stages of development, NK cell subsets have distinct functional roles. The association of these to human disease has only been minimally explored and will rely upon a robust appreciation of normal human ranges.

In addition to NK cell development, particular NK cell receptors enable specific NK cell functions. Some of these detect signatures of danger to induce NK cell function, while others identify characteristics of health to restrain NK cell activities. The topic of functionally diverse NK cell receptors has been reviewed extensively [7] [8] [9]. Those considered in the current study with regards to considering local healthy donor ranges are listed in Table 1.

While there have been several studies of extended human NK cell phenotypes, few have focused on the establishment of normative ranges and none to our knowledge has considered the extended phenotype variability over time in specific healthy individuals. Thus, we evaluated a pool of 40 adult healthy donors by multi-parametric flow cytometry using an NK cell phenotype panel in an effort to establish normative ranges. We combine this with a study of intra-individual variability in a subset of individuals in an effort to define normal acceptable alterations in NK cell receptor expression over time.

Materials and Methods

2.1 Human NK cell preparation

PBMCs were isolated from whole blood of normal donors by density centrifugation over Ficoll-Hypaque lymphocyte isolation medium (GE Healthcare Life Sciences). All human samples were obtained using written informed donor consent and were used with the approval of the Children's Hospital of Philadelphia and/or Baylor College of Medicine Institutional Review Boards for the Protection of Human Subjects. Three donors were used for the study of individual variation at intervals ranging from 1 week to 2 years.

2.2 NK cell phenotyping, flow cytometry, and analysis

Following density centrifugation, 2.5×10^5 PBMCs were washed once in FACS buffer [1% bovine serum albumin (BSA) in phosphate buffered saline (PBS)]. For biotinylated antibodies (anti-CD11b and anti-CD122) 10 μ l of antibody was added to tubes and incubated for 15–20 minutes at room temperature in the dark, followed by 1 μ l of streptavidin-conjugated 488 for an additional 15–20 minutes. All Staining was done in 100 μ l of FACS buffer. Other surface marker antibodies or isotypic controls were then added (1:100), including anti-CD3 and anti-CD56, and incubated 15–20 minutes (Table 2). Cells were

washed twice with FACS buffer and resuspended in 300 μ l FACS buffer plus 200 μ l 2% paraformaldehyde. If intracellular staining was performed, 500 μ l of pre-warmed CytoFix/Cytoperm (BD Biosciences) was added to tubes following surface marker staining and incubated for 15 minutes at room temperature. Cells were washed twice with Cytoperm wash buffer and specific antibody added (e.g. anti-perforin) and incubated for 15–30 minutes. Cells were washed twice with Cytoperm wash buffer. All samples were analyzed on a FACSCalibur™ flow cytometer (BD Biosciences). PBMCs were gated based upon forward and side scatter to allow for identification of lymphocytes. Positive and negative thresholds for fluorescence signals were defined using isotype-specific negative controls. NK cells were delineated as lymphocytes that were CD56⁺CD3⁻. The fluorescence intensity of CD56 staining was used to identify CD56^{bright} NK cells and, when necessary, the demarcation between CD56^{bright} and CD56^{dim} populations was further confirmed using CD16 on NK cells to identify the CD56^{dim}CD16⁺ population. For detailed NK cell surface marker evaluation, the frequency of positive events was measured as those CD56⁺CD3⁻ cells expressing the marker of interest above that of isotype-matched negative control. All flow cytometric analyses were performed using FlowJo (Treestar, Inc.). Prism 5.0 (GraphPad Software) was used for all graphing and statistical analyses.

3. Results

To ascertain the variation in NK cell populations across a pool of healthy adult donors (n=40), a repertoire of twenty surface receptors was evaluated (Table 1). For three of these donors longitudinal data were obtained over three years. Lymphocytes were identified by FSC-SSC and NK cells were defined as CD56⁺CD3⁻ (see Supplemental Figure for gating strategy). The total number of CD56⁺CD3⁻ NK cells found in the peripheral blood varied widely among normal donors as a proportion of PBMC (0.61 – 16.87%), with a mean of 6.47% (Table 3). When evaluated over time in three individual longitudinal donors total NK cells comprised a mean of 8.79 $\pm$ 3.31, 9.54 $\pm$ 1.96, and 5.34 $\pm$ 2.23% of PBMCs across 3–7 longitudinal assessments (Fig 1a). CD56^{dim} NK cells comprise 90% of peripheral blood NK cells [10, 11], and our findings are consistent (mean=90.20 $\pm$ 6.84%, range 61.68 – 98.29%). CD56^{bright} NK cells generally comprise 10% of peripheral NK cells which was also what was identified in our cohort; mean = 8.56 $\pm$ 6.90%, range 0.63 – 38.32. Mean percentages of CD56^{bright} NK cells were relatively similar amongst our three longitudinal donors but varied considerably over time within each donor (Fig. 1b). As would be expected, the same was true for the mean percentages and intra-individual variability of CD56^{dim} NK cells (Fig. 1c).

3.1 Activating and accessory molecules

Activating and costimulatory molecules facilitate the cytotoxic function of mature NK cells and serve developmental functions in developing NK cells. As expected, a greater proportion of CD56^{dim} NK cells expressed perforin and CD16, and they were also present at higher levels (perforin: 68.34%+, MFI 41.94; CD16: 54.38%+, MFI 85.38) than on CD56^{bright} NK cells (perforin 16.15%+, MFI 15.26; CD16 26.32%+, MFI 34.53) (Table 3, Fig 2b, c). CD8 α was also expressed as expected and was variable between donors (total NK cells 39.33 $\pm$ 16.75%, range 8.92 – 77.3) (Fig 2a) [12], although in our cohort CD56^{bright}

NK cells expressed slightly less CD8 α than previously published (34%) as did the CD56^{dim} subset (39%) (Fig. 2c) [13]. CD2 can serve as a costimulatory receptor on NK cells as resting NK cells can be primed by CD2 ligation with CD58 [14]. While 72% of total NK cells expressed CD2 (Fig 2a), including 69.4% of CD56^{dim} NK cells and 94.1% of CD56^{bright} (Fig 2c), the MFI was higher in the CD56^{bright} subset (693 ± 449) than the CD56^{dim} subset (228 ± 154) (Fig 2b). Adhesion molecules CD11a, CD11b, and CD18 were highly expressed both on CD56^{bright} and CD56^{dim} NK cells and at similar levels (Fig 2). DNAM-1, recently ascribed in murine models to have important roles in the generation of NK cell memory [15], was expressed on both CD56^{bright} and CD56^{dim}, although the range among donors varied substantively in both subsets (Table 3, Fig. 2c).

CD94 forms heterodimers with both NKG2A (inhibitory) and NKG2C (activating) receptors and as such is more uniformly associated with the CD56^{bright} population, although a subset of CD56^{dim} also expresses CD94 and are thought to represent an intermediate population in the potential maturation of CD56^{bright} to CD56^{dim} NK cells [16]. As would be expected in our donors CD94 was present on a higher percentage of CD56^{bright} (82.2 ± 19.4) (Fig. 2c) and these also had a higher density of expression (MFI 57.1 ± 29.0) (Fig. 2b) than those CD56^{dim} NK cells that express CD94 ($38.7 \pm 18.6\%$; MFI 15.9 ± 10.5) (Table 3, Fig. 2). Within individual donors, CD94 expression remained relatively stable in terms of both percentage and MFI (Fig 3).

2B4 (CD244) was expressed on approximately 35% of total NK cells, with a slightly higher frequency of CD56^{dim} (35.6%) than CD56^{bright} NK cells (22.9%) expressing comparable densities of CD244 (Table 3, Fig. 2). The cell stress sensing activating receptor, NKG2D, was expressed on both CD56^{bright} and CD56^{dim} NK cells although the mean percent positive and MFI were higher on CD56^{bright} (73.3%; MFI 34) than CD56^{dim} NK cells (47.6; MFI 17) (Fig 2b, c). NKp30 and NKp46 are natural cytotoxicity receptors (NCR) that can promote NK cell activation and can participate in the recognition of rapidly dividing as well as certain types of virally infected cells [17]. The expression of NKp46 was diffuse although the mean percentage and MFI of NKp46 positive cells was higher on CD56^{bright} (76.4%; MFI 49.4) than CD56^{dim} (40.5%; MFI 20.3) NK cells. In contrast, NKp30 was expressed on approximately the same low percentage of both NK cell subsets, with very similar MFIs (Table 3, Fig 2b, c).

NK cells express the IL-2 receptor and are highly responsive to this cytokine [18]. CD56^{dim} NK cells express the intermediate affinity form of the IL-2 receptor, composed of CD122 (IL-2 receptor β chain) and CD132 (common γ chain), whereas CD56^{bright} can express the trimeric high affinity receptor, consisting of the intermediate form in complex with CD25 (the IL-2 receptor α chain). Therefore, CD56^{bright} NK cells proliferate in response to low IL-2 concentrations (picomolar range), whereas CD56^{dim} cells are less responsive *in vitro* to even higher concentrations [10]. In agreement with prior observations CD122 was expressed on both CD56^{bright} and CD56^{dim} NK cell subsets in our cohort [10] and levels were similar on CD56^{bright} and CD56^{dim} NK cells (Fig 2b, c). In this study, levels of CD132 and CD25 were not tested.

3.2 Inhibitory receptors

The ligation of certain NK cell receptors by specific major histocompatibility complex (MHC) molecules inhibits the cytotoxic function of mature NK cells as a mechanism to prevent errant self-destruction or inflammation as well as allows for the “licensing” of immature NK cells so that they may be enabled for function. Many of these receptors are members of the killer immunoglobulin receptor family (KIR). Antibodies against CD158a (KIR2DL1), CD158b (KIR2DL2), and CD158e1 (KIR3DL1) were used in our study. As the KIR locus is both polymorphic and subject to allelic variability, expression would be expected to vary among donors. Furthermore, KIR expression is a signature of maturation and thus CD56^{dim} NK cells express KIRs on a larger percentage of cells [7]. As expected, a higher percentage of CD56^{dim} NK cells expressed KIRs when in aggregate compared to CD56^{bright} NK cells (Fig 2c). There was, however, some KIR expression within the overall CD56^{bright} population. Ten out of 37, 21/37, and 14/37 donors expressed CD158a, CD158b, and CD158e1, respectively, on their CD56^{bright} NK cells. KIR expression was highly variable on the CD56^{dim} NK cell subset. Of the three KIRs examined, CD158b was the most highly expressed on CD56^{dim} NK cells however the MFI for CD158e1 was the highest of all three KIRs, demonstrating that MFI and percent positivity are unrelated with regard to KIR expression (Table 3, Fig 2d). As expected, KIR expression within individual donors over time was relatively stable (Fig 3).

3.3 Differentiation/maturity markers

NK cell maturation is staged based on the coordinated expression of cell surface markers throughout development [5]. Discrete subsets are based on the expression of multiple receptors including some of those referred to in prior sections. Owing to the experimental design of the current work, receptors here were considered individually. CD27 is a member of the TNF receptor family ligated by CD70 and is expressed on immature and CD56^{bright} NK cells. While it is considered to be a fundamental marker of NK cell maturation state, it is itself not required for human NK cell development [19]. As expected, there were fewer CD27-expressing CD56^{dim} NK cells (10.7%) than CD56^{bright} NK cells (33.5%) (Table 3, Fig 2c). CD117 (c-kit) was expressed on at least ten times as many CD56^{bright} (72.4%) as CD56^{dim} NK cells (5.94%) with the MFI also higher (CD56^{bright} 18.0; CD56^{dim} 13.2) (Fig 2b, c). This is in agreement with prior studies and reflects the importance of this receptor in NK cell development [20] [5]).

CD57 denotes terminal maturation for CD56^{dim} NK cells and is increased following cytomegalovirus infection [21], [22]. As expected, CD57 was more highly expressed on the CD56^{dim} NK cell subset, particularly when considered with regards to MFI (CD56^{bright} 113.6; CD56^{dim} 792) (Table 3, Fig 2b). Perforin is also associated with terminal NK cell maturation and is expressed at lower levels in less mature CD56^{bright} NK cells [23]. As described above, intracellular evaluations identified a small percentage of CD56^{bright} (16%) but many CD56^{dim} (68.3%) NK cells contain perforin at levels above background (Table 3, Fig 2c). Perforin content in individual donors over time showed a range of 45–92% in total NK cells, and was considerably higher in the CD56^{dim} subset than the CD56^{bright} NK cells in both percent positive and MFI (Figs 3, 4, 5).

3.4 Individual variability in NK cell receptors over time

In terms of percent positive NK cells, our three donors evaluated longitudinally had several markers in common that showed little variability over time, including CD158a, NKB1 (CD158e1), CD158b, CD8, CD11a, CD27, NKp30, CD117, CD18, and CD57 (Fig 3). In addition, several markers appear to have consistent expression amongst all three donors (CD158a, NKB1, CD158b, CD8, and CD27). The MFI of many markers was more consistent among the three donors than percent positive cells, suggesting levels of surface receptor expression are relatively conserved between subjects, whereas variability arises from the frequency of expression within the population.

Differences in the expression patterns of the receptors were also considered in the specific context of CD56^{bright} and CD56^{dim} subsets over time for each donor. As seen in the total NK cell population, the MFIs for the markers were less variable than the percent positive cells in both the CD56^{bright} and CD56^{dim} subsets for all three donors (Fig 4, 5). The KIRs (CD158a, CD158b, and NKB1) retained low overall mean MFIs in the CD56^{bright} subset over time, while the CD56^{dim}s displayed higher MFI and less variability (Fig 4, 5). Accessory molecules, including CD2, did not vary greatly over time in the CD56^{bright} subset. CD2 was highly expressed on CD56^{bright} NK cells from all time points (Fig 4). CD2 was expressed over a much broader range of percent positive cells for the CD56^{dim} population in all three donors, and there was more variability in CD2 expression in the CD56^{dim} subset over time (Fig 5). CD11a and CD18 were expressed at very high and very consistent levels over all time points in both subsets. CD11b showed more variation, both among and within donors. CD16 expression fluctuated on the CD56^{dim} subpopulation for all three donors; however, CD16 expression was also quite variable in the CD56^{bright} NK cell subset over time. Donor B's CD56^{bright} cells were 38% CD16⁺ and did not fluctuate in the same manner as Donors A and C (Fig 4).

Expression of activation receptors CD94, NKp46, DNAM1, NKG2D, and CD244 varied over time (Fig 3). NKp30 expression on CD56^{bright} NK cells was very low in all three donors with the greatest variability in Donor A (Fig 4). In the CD56^{dim} subset NKp30 was quite stable and consistently expressed at low levels over time (Fig 5). CD57 showed transient low expression on CD56^{bright} NK cells for each of the donors (Fig 4). In the CD56^{dim} subset, CD57 was more moderately and consistently expressed in terms of percent positive cells (Donor A 29.8%; Donor B 38.1%; and Donor C 25.9%) but was slightly more variable in Donor C than in Donors A and B (Fig 5). CD56^{dim} cells exhibited consistent perforin with a mean expression of 61.9, 65.6, and 59.6% for Donors A, B, and C, respectively, whereas in CD56^{bright} cells it was more variable (Fig 4). The range of perforin positive CD56^{dim} cells was 47.4 – 77.7% for Donor A; 51.5 – 89.3% for Donor B; and 45.5 – 74.5% for Donor C (Fig 5).

4. Discussion

Our laboratory has engaged in the discovery of NK cell abnormalities amongst heritable immune defects [2]. The assessment of NK cell receptor expression in peripheral blood provides utility by furthering our understanding of how normal NK cell receptor expression varies across a pool of normal donors and is modulated over time in a given individual. This

is an essential prerequisite to being able to understand what might be abnormal. Thus, we examined a repertoire of twenty different NK cell receptors in both CD56^{bright} and CD56^{dim} NK cell subsets in a healthy adult population and also monitored changes in these receptors in three donors over time. By using a standardized and rigorous approach to data acquisition and analysis, we are thus able to make quantitative comparisons of NK cell receptor distribution within a large, ethnically diverse population, as well as within three healthy and immunologically normal adults.

Several immunodeficiencies present with decreased NK cell frequency, and classical NK cell deficiency is defined clinically when NK cells are <1% of PBMC [3]. Generally, NK cells comprise ~10% of lymphocytes in peripheral blood. Our data, which includes a relatively large cohort of healthy adults, reflects a wide range of NK cells within the lymphocyte compartment as reported previously [4]. The mean, however, places most donors within previously determined normal ranges. Within the same individual over time there was also variation in NK cell numbers, with each donor ranging from approximately 2–11% NK cells within PBMC over as little as seven months. This plasticity in NK cell number may relate to lifestyle and environment as many variables, including brief exercise, have been shown to affect NK cell numbers within peripheral blood [24]. This may also reflect unappreciated non-clinically apparent immune events that were contributing to altered homeostasis in the donor at the time.

A further complexity of human NK cell function is the presence of the CD56^{bright} and CD56^{dim} subsets, which reflect both developmental stages and discrete functional elements. As CD56^{dim} NK cells make up the majority of the NK cell population in peripheral blood, the graphs depicting total NK cells are more reflective of the CD56^{dim} phenotype than the CD56^{bright}, thus examining both subsets is important in potentially determining NK cell defects in patient populations. In addition, the relative proportion of the populations to each other is linked to known diseased states. Most notably, GATA2 mutation is associated with loss of the CD56^{bright} NK cell subset [4], whereas mutation in the MCM4 gene results in a paucity of CD56^{dim} NK cells [25]. Both disorders are associated with severe accompanying NK cell functional defects. Our data indicate that a wide range of CD56^{bright} and CD56^{dim} NK cells may be considered normal amongst individuals, or notably within the same individual over time.

For the most part, our measure of the expression of NK cell surface receptors reflected the known distinct CD56^{bright} and CD56^{dim} phenotypes. CD94, DNAM-1, NKG2D, and NKp46 were expressed on a higher percentage of CD56^{bright} NK cells. NKp30, however, was expressed equally in CD56^{bright} and CD56^{dim} subsets. Overall higher expression of these activating receptors in the CD56^{bright} subset was consistent over time for all three individual donors, but the levels fluctuated. 2B4 (CD244) was expressed at lower levels in CD56^{bright} cells, although there was some variation both within and among donors. The lower mean percent positive expression of 2B4 in CD56^{bright} cells is probably due to the fact that 6 out of 29 donors interrogated for this marker did not express any 2B4 on their CD56^{bright} NK cells, while all donors expressed 2B4 on their CD56^{dim} cells.

CD57 is typically considered a marker of maturity for CD56^{dim} NK cells that is acquired following human cytomegalovirus (HCMV) infection, and may be a marker for HCMV memory [21], [22]. All donors expressed CD57 on their CD56^{dim} NK cells. In contrast, 11/23 donors had 0% CD57+ cells within the CD56^{bright} subset. As reported previously, there was a wide range of CD57 expression among donors on CD56^{dim} NK cells [21]. DNAM-1 up-regulation is also associated with the acquisition of NK cell memory in mice [15], therefore the higher expression of DNAM1 on CD56^{bright} in many donors is interesting given its potential association with a terminally differentiated CD56^{dim} population.

Within almost all markers investigated there was a significant range amongst donors. The exception was KIRs, which individually were not expressed on as many individuals' NK cells, and CD8. This variation reflects the recent studies using mass cytometry that identified as many as 30,000 unique NK cell populations within an individual and >100,000 within the population [26]. This diversity, which is a feature of both genetics and environment, is proposed to represent multiple NK cell sub-populations [26]. The greater diversity in frequency of receptor-positive cells, as opposed to MFI, suggests that there is less variation in the surface density of molecules expressed than there is in the number of cells expressing the marker of interest. The inclusion of MFI in our study is valuable, however, as many mass cytometry studies use Boolean logic for gating, and thus assign a binary (positive/negative) label on each marker. As a number of disease states may ultimately affect levels of receptor expression [4] [27], continued focus on receptor density will likely have a valuable role.

Regarding individual variation in NK cell receptors over time, Donors B and C had a similar time frame of 7 or 8 months overall, whereas Donor A's samples spanned three years, hence these time points provide only a brief snapshot of the variation of NK cell receptor expression over time. These snapshots, however, reveal considerable variation in receptor and NK cell subset distribution. As expected, however, KIR expression remained fairly stable in all donors.

Several markers included in our panel have been linked to NK cell deficiency and as such are particularly valuable. These include the CD16 B73.1 clone, as diminished binding of this antibody accompanied by normal binding of the 3G8 clone is associated with CD16 deficiency [28]. CD27 deficiency results in NK cell functional defects and EBV viremia [19]. Perforin deficiency results in deficiency of NK cell cytotoxicity and susceptibility to hematophagocytic lymphohistiocytosis [29]. Leukocyte adhesion deficiency-I is a result of mutations in the *ITGB2* gene that encodes LFA-1, resulting in destabilized expression of CD18 and loss of LFA-1 expression. As noted previously, mutations in both *MCM4* and *GATA2* result in skewing of the CD56^{bright} to CD56^{dim} ratio and each are associated with NK cell dysfunction and accompanying disease. By continuing to define normal ranges for those markers associated with disease, we aim to improve the accuracy and impact of diagnoses of NK cell deficiency and related syndromes, which lead to severe and often fatal disease. It will be important in future work to define NK cell phenotypes in children to establish age-specific normal ranges. Our results presented here, however, demonstrate significant plasticity of the NK cell compartment amongst and within healthy human adults, in terms of both subset distribution and receptor expression.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *The Journal of Allergy and Clinical Immunology*. 2003; 112:973–80. [PubMed: 14610491]
2. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. *Frontiers in Immunology*. 2014; 5:162. [PubMed: 24795713]
3. Orange JS. Natural killer cell deficiency. *The Journal of Allergy and Clinical Immunology*. 2013; 132:515–25. [PubMed: 23993353]
4. Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, Dropulic L, Cohen JI, Frenkel EP, Bagwell JC, Sullivan JL, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. *Blood*. 2013; 121:2669–77. [PubMed: 23365458]
5. Freud AG, Caligiuri MA. Human natural killer cell development. *Immunological Reviews*. 2006; 214:56–72. [PubMed: 17100876]
6. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. *Trends in immunology*. 2013; 34:573–82. [PubMed: 24055329]
7. Thielens A, Vivier E, Romagne F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. *Current Opinion in Immunology*. 2012; 24:239–45. [PubMed: 22264929]
8. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. *Nature Immunology*. 2008; 9:495–502. [PubMed: 18425106]
9. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. *Frontiers in Immunology*. 2014; 5:305. [PubMed: 25071766]
10. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends in Immunology*. 2001; 22:633–40. [PubMed: 11698225]
11. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcR3-positive and negative natural killer cells. *Journal of Immunology*. 1989; 143:3183–91.
12. Morice WG. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. *American Journal of Clinical Pathology*. 2007; 127:881–86. [PubMed: 17509985]
13. Beziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadiere B, Debre P, Vieillard V. CD56bright, CD16+ NK cells: a functional intermediate stage of NK cell differentiation. *Journal of Immunology*. 2011; 186:6753–61.
14. Sabry M, Tsirogianni M, Bakhsh IA, North J, Sivakumaran J, Giannopoulos K, Anderson R, Mackinnon S, Lowdell MW. Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors. *Journal of Immunology*. 2011; 187:6227–34.
15. Nabekura T, Kanaya M, Shibuya A, Fu G, Gascoigne NR, Lanier LL. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. *Immunity*. 2014; 40:225–34. [PubMed: 24440149]
16. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. *Blood*. 2010; 115:274–81. [PubMed: 19897577]
17. Li Y, Mariuzza RA. Structural basis for recognition of cellular and viral ligands by NK cell receptors. *Frontiers in Immunology*. 2014; 5:123. [PubMed: 24723923]

18. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. *Nature*. 1981; 291:335–8. [PubMed: 6164929]
19. van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA, Monaco-Shawver L, Banerjee PP, Sanders EA, Jol-van der Zijde CM, et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. *The Journal of Allergy and Clinical Immunology*. 2012; 129:787–93. e786. [PubMed: 22197273]
20. Pradier A, Tabone-Eglinger S, Huber V, Bosshard C, Rigal E, Wehrle-Haller B, Roosnek E. Peripheral blood CD56(bright) NK cells respond to stem cell factor and adhere to its membrane-bound form after upregulation of c-kit. *European journal of immunology*. 2014; 44:511–20. [PubMed: 24150691]
21. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. *Blood*. 2010; 116:3865–74. [PubMed: 20733159]
22. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:14725–32. [PubMed: 21825173]
23. Krzewski K, Coligan JE. Human NK cell lytic granules and regulation of their exocytosis. *Frontiers in Immunology*. 2012; 3:335. [PubMed: 23162553]
24. Millard AL, Valli PV, Stussi G, Mueller NJ, Yung GP, Seebach JD. Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation. *Frontiers in Immunology*. 2013; 4:125. [PubMed: 23755049]
25. Gineau L, Cognet C, Kara N, Lach FP, Dunne J, Veturi U, Picard C, Trouillet C, Eidenschenk C, Aoufouchi S, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. *The Journal of Clinical Investigation*. 2012; 122:821–32. [PubMed: 22354167]
26. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, Dekker CL, Mackey S, Maecker H, Swan GE, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. *Science Translational Medicine*. 2013; 5:208ra145.
27. Shaw RK, Issekutz AC, Fraser R, Schmit P, Morash B, Monaco-Shawver L, Orange JS, Fernandez CV. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. *Blood*. 2012; 119:4009–12. [PubMed: 22427204]
28. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, Campbell KS, Orange JS. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. *The Journal of Clinical Investigation*. 2012; 122:3769–80. [PubMed: 23006327]
29. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. *The Journal of Clinical Investigation*. 2006; 116:182–92. [PubMed: 16374518]
30. Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. *Proceedings of the National Academy of Sciences of the United States of America*. 1987; 84:3365–9. [PubMed: 2437578]
31. Sewell WA, Brown MH, Dunne J, Owen MJ, Crumpton MJ. Molecular cloning of the human T-lymphocyte surface CD2 (T11) antigen. *Proceedings of the National Academy of Sciences of the United States of America*. 1986; 83:8718–22. [PubMed: 3490670]
32. Comerici CJ, Mace EM, Banerjee PP, Orange JS. CD2 promotes human natural killer cell membrane nanotube formation. *PloS One*. 2012; 7:e47664. [PubMed: 23112830]
33. Zheng X, Wang Y, Wei H, Sun R, Tian Z. LFA-1 and CD2 synergize for the Erk1/2 activation in the Natural Killer (NK) cell immunological synapse. *The Journal of Biological Chemistry*. 2009; 284:21280–7. [PubMed: 19502238]
34. Nakayama K, Kawachi Y, Tokito S, Minami N, Yamamoto R, Imai T, Gachelin G, Nakauchi H. Recent duplication of the two human CD8 beta-chain genes. *Journal of Immunology*. 1992; 148:1919–27.

35. Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW. Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. *Immunology*. 2005; 116:354–61. [PubMed: 16236125]
36. Rodriguez AR, Arulanandam BP, Hodara VL, McClure HM, Cobb EK, Salas MT, White R, Murthy KK. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. *The Journal of General Virology*. 2007; 88(Pt 2):641–51. [PubMed: 17251583]
37. Corbi AL, Larson RS, Kishimoto TK, Springer TA, Morton CC. Chromosomal location of the genes encoding the leukocyte adhesion receptors LFA-1, Mac-1 and p150,95. Identification of a gene cluster involved in cell adhesion. *The Journal of Experimental Medicine*. 1988; 167:1597–1607. [PubMed: 3284962]
38. Wang H, Zheng X, Wei H, Tian Z, Sun R. Important role for NKp30 in synapse formation and activation of NK cells. *Immunological Investigations*. 2012; 41:367–81. [PubMed: 22221078]
39. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. *The Journal of Experimental Medicine*. 2005; 202:1001–12. [PubMed: 16203869]
40. Sadhu C, Harris EA, Staunton DE. Enhancement of Natural Killer cell cytotoxicity by a CD18 integrin-activating antibody. *Biochemical and Biophysical Research Communications*. 2007; 358:938–41. [PubMed: 17512497]
41. Corbi AL, Kishimoto TK, Miller LJ, Springer TA. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. *The Journal of Biological Chemistry*. 1988; 263:12403–11. [PubMed: 2457584]
42. Arnaout MA, Remold-O'Donnell E, Pierce MW, Harris P, Tenen DG. Molecular cloning of the alpha subunit of human and guinea pig leukocyte adhesion glycoprotein Mo1: chromosomal localization and homology to the alpha subunits of integrins. *Proceedings of the National Academy of Sciences of the United States of America*. 1988; 85:2776–80. [PubMed: 2833753]
43. Orange JS, Chehimi J, Ghavimi D, Campbell D, Sullivan KE. Decreased natural killer (NK) cell function in chronic NK cell lymphocytosis associated with decreased surface expression of CD11b. *Clinical Immunology*. 2001; 99:53–64. [PubMed: 11286541]
44. Arnaout MA, Gupta SK, Pierce MW, Tenen DG. Amino acid sequence of the alpha subunit of human leukocyte adhesion receptor Mo1 (complement receptor type 3). *The Journal of Cell Biology*. 1988; 106:2153–8. [PubMed: 2454931]
45. Ornstein BW, Hill EB, Geurs TL, French AR. Natural killer cell functional defects in pediatric patients with severe and recurrent herpesvirus infections. *The Journal of Infectious Diseases*. 2013; 207:458–68. [PubMed: 23175766]
46. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. *The Journal of Experimental Medicine*. 1989; 170:481–97. [PubMed: 2526846]
47. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. *Science*. 1990; 248:732–5. [PubMed: 2139735]
48. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). *Clinical and Experimental Immunology*. 1996; 103:408–13. [PubMed: 8608639]
49. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*. 1999; 96:5640–4. [PubMed: 10318937]
50. Axberg I, Ramstedt U, Patarroyo M, Beatty P, Wigzell H. Inhibition of natural killer cell cytotoxicity by a monoclonal antibody directed against adhesion-mediating protein gp 90 (CD18). *Scandinavian Journal of Immunology*. 1987; 26:547–54. [PubMed: 2961052]

51. Liu JH, Wei S, Blanchard DK, Djeu JY. Restoration of lytic function in a human natural killer cell line by gene transfection. *Cellular Immunology*. 1994; 156:24–35. [PubMed: 7911075]
52. Timonen T, Patarroyo M, Gahmberg CG. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. *Journal of immunology*. 1988; 141:1041–6.
53. Bigler RD, Bushkin Y, Chiorazzi N. S152 (CD27). A modulating disulfide-linked T cell activation antigen. *Journal of Immunology*. 1988; 141:21–8.
54. Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, Hamann J, Kuijpers TW, van Lier RA. CD27 defines phenotypically and functionally different human NK cell subsets. *Journal of Immunology*. 2008; 180:3739–45.
55. Fu B, Tian Z, Wei H. Subsets of human natural killer cells and their regulatory effects. *Immunology*. 2014; 141:483–9. [PubMed: 24303897]
56. Mitsumoto Y, Oka S, Sakuma H, Inazawa J, Kawasaki T. Cloning and chromosomal mapping of human glucuronyltransferase involved in biosynthesis of the HNK-1 carbohydrate epitope. *Genomics*. 2000; 65:166–73. [PubMed: 10783264]
57. Yamamoto S, Oka S, Inoue M, Shimuta M, Manabe T, Takahashi H, Miyamoto M, Asano M, Sakagami J, Sudo K, et al. Mice deficient in nervous system-specific carbohydrate epitope HNK-1 exhibit impaired synaptic plasticity and spatial learning. *The Journal of Biological Chemistry*. 2002; 277:27227–31. [PubMed: 12032138]
58. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. *European Journal of Immunology*. 1995; 25:2433–7. [PubMed: 7589107]
59. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. *The Journal of Experimental Medicine*. 1998; 187:813–8. [PubMed: 9480992]
60. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JL, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature*. 1998; 391:795–9. [PubMed: 9486650]
61. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proceedings of the National Academy of Sciences of the United States of America*. 1998; 95:5199–204. [PubMed: 9560253]
62. Vandenbark GR, deCastro CM, Taylor H, Dew-Knight S, Kaufman RE. Cloning and structural analysis of the human c-kit gene. *Oncogene*. 1992; 7:1259–66. [PubMed: 1377810]
63. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. *The Journal of Experimental Medicine*. 1993; 178:1079–84. [PubMed: 7688785]
64. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. *Proceedings of the National Academy of Sciences of the United States of America*. 1994; 91:7553–7. [PubMed: 7519782]
65. Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. *European Journal of Immunology*. 1997; 27:354–60. [PubMed: 9045904]
66. Benson DM Jr, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. *Blood*. 2009; 113:2706–14. [PubMed: 19060242]
67. Fehniger TA, Carson WE, Mrozek E, Caligiuri MA. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. *Blood*. 1997; 90:3647–53. [PubMed: 9345049]
68. Di Santo JP, Rodewald HR. In vivo roles of receptor tyrosine kinases and cytokine receptors in early thymocyte development. *Current Opinion in Immunology*. 1998; 10:196–207. [PubMed: 9602309]

69. Tsudo M, Kitamura F, Miyasaka M. Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. *Proceedings of the National Academy of Sciences of the United States of America*. 1989; 86:1982–6. [PubMed: 2467293]
70. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. *Nature Reviews Immunology*. 2006; 6:595–601.
71. Carson WE, Fehniger TA, Halder S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA. A potential role for interleukin-15 in the regulation of human natural killer cell survival. *The Journal of Clinical Investigation*. 1997; 99:937–43. [PubMed: 9062351]
72. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. *Science*. 1995; 268:405–8. [PubMed: 7716543]
73. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. *Immunity*. 1995; 2:439–49. [PubMed: 7749980]
74. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL. Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes. *Journal of immunology*. 1995; 155:2306–10.
75. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, Accame L, Bottino C, Moretta A, Moretta L. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. *The Journal of Experimental Medicine*. 1996; 184:505–18. [PubMed: 8760804]
76. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunity*. 1996; 4:573–81. [PubMed: 8673704]
77. Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E, Nakauchi H, Shibuya A. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. *Immunity*. 1999; 11:615–23. [PubMed: 10591186]
78. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *The Journal of Experimental Medicine*. 2003; 198:557–67. [PubMed: 12913096]
79. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K, Shibuya A. Accelerated tumor growth in mice deficient in DNAM-1 receptor. *The Journal of Experimental Medicine*. 2008; 205:2959–64. [PubMed: 19029379]
80. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. *Journal of Immunology*. 2010; 184:902–11.
81. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, Lazzeri E, Lasagni L, Martini S, Rivera P, et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. *Blood*. 2006; 107:2030–6. [PubMed: 16304049]
82. Hou S, Ge K, Zheng X, Wei H, Sun R, Tian Z. CD226 protein is involved in immune synapse formation and triggers Natural Killer (NK) cell activation via its first extracellular domain. *The Journal of Biological Chemistry*. 2014; 289:6969–77. [PubMed: 24451371]
83. Hou S, Zheng X, Wei H, Tian Z, Sun R. Recombinant soluble CD226 protein directly inhibits cancer cell proliferation in vitro. *International Immunopharmacology*. 2014; 19:119–26. [PubMed: 24468679]
84. Boles KS, Nakajima H, Colonna M, Chuang SS, Stepp SE, Bennett M, Kumar V, Mathew PA. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4. *Tissue Antigens*. 1999; 54:27–34. [PubMed: 10458320]

85. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. *The Journal of Experimental Medicine*. 1998; 188:2083–90. [PubMed: 9841922]
86. Bryceon YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood*. 2006; 107:159–66. [PubMed: 16150947]
87. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. *The Journal of Experimental Medicine*. 1991; 173:1017–20. [PubMed: 2007850]
88. Yabe T, McSherry C, Bach FH, Fisch P, Schall RP, Sondel PM, Houchins JP. A multigene family on human chromosome 12 encodes natural killer-cell lectins. *Immunogenetics*. 1993; 37:455–60. [PubMed: 8436421]
89. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science*. 1999; 285:727–9. [PubMed: 10426993]
90. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. *Annual Review of Immunology*. 2013; 31:413–41.
91. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. *Oncoimmunology*. 2013; 2:e26097. [PubMed: 24353908]
92. Lopez-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S. NKG2D signaling in cancer immunosurveillance. *International Journal of Cancer Journal international du cancer*. 2014
93. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. *The Journal of Experimental Medicine*. 1998; 188:953–60. [PubMed: 9730896]
94. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, Hanna J, Qimron U, Landau G, Greenbaum E, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene *Ncr1*. *Nature Immunology*. 2006; 7:517–23. [PubMed: 16565719]
95. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. *Frontiers in Immunology*. 2013; 4:69. [PubMed: 23518691]
96. Thoren FB, Riise RE, Ousback J, Della Chiesa M, Alsterholm M, Marcenaro E, Pesce S, Prato C, Cantoni C, Bylund J, et al. Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism. *Journal of Immunology*. 2012; 188:1668–74.
97. Podack ER, Lowrey DM, Lichtenheld M, Olsen KJ, Aebischer T, Binder D, Rupp F, Hengartner H. Structure, function and expression of murine and human perforin 1 (P1). *Immunological Reviews*. 1988; 103:203–11. [PubMed: 3292394]
98. Shinkai Y, Takio K, Okumura K. Homology of perforin to the ninth component of complement (C9). *Nature*. 1988; 334:525–7. [PubMed: 3261391]
99. Voskoboinik I, Trapani JA. Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. *Frontiers in Immunology*. 2013; 4:441. [PubMed: 24376445]

Fig. 1. Variation in NK cell frequency and subsets over time

PBMCs from healthy donor controls were analyzed by flow cytometry as described in Materials and Methods. Percent total NK cells in PBMC were defined as CD56⁺CD3⁻ (a). CD56^{bright} (b) and CD56^{dim} (c) subsets were defined by CD56 density and/or CD16 expression. Each data point represents one evaluation. n=7, 3, and 3 for Donors A, B, and C respectively. Mean±SD are shown.

Fig. 2. Expression of markers on human NK cells derived from healthy donors

NK cells were identified as CD56⁺CD3⁻. a) Expression of markers of interest was calculated based on MFI (black, left Y axis) or percent positive above isotype control (white, right Y axis). b) MFI of markers of interest is shown for CD56^{bright} (black) and CD56^{dim} (white). c) % positive expression of markers of interest above isotype are shown for CD56^{bright} (black) and CD56^{dim} (white). n=22–40. Mean±SD are shown. d) MFI (top) or percent positive (bottom) of KIRs studied on total NK cells for each donor N=40. All bars demonstrate surface expression except for perforin, which demonstrates intracellular detection through use of a separate protocol (see *Methods*).

Fig. 3. Variation in NK cell marker expression in three healthy donors over time

Three individual donors were followed over time for changes in the expression of NK cell markers within the CD56⁺CD3⁻ NK cell population. Each data point represents a single evaluation (n=3–7). Expression of markers of interest is shown as MFI (left) or % positive above isotype (right). Mean±SD are shown. The longitudinal assessments cover time periods in total between 7mos and 3yrs depending upon the donor tested.

Fig. 4. Variation in NK cell marker expression on CD56^{bright} cells in healthy donors over time. CD56^{bright} NK cells were identified as in Figure 1 and markers of interest are shown as in Figure 3.

Fig. 5. Variation in marker expression on CD56^{dim} NK cells in healthy donors over time
CD56^{dim} NK cells were identified as in Figure 1 and markers of interest are shown as in Figure 3.

Table 1

NK cell receptors and functions.

Marker	Aliases	Function in NK cells	References
CD2	Sheep Red Blood Cell Receptor, Erythrocyte Receptor, Rosette Receptor, LFA-2, LFA-3 Receptor, T-cell surface antigen T11/Leu-5.	Nanotube formation in NK cells; Priming of resting NK cells; Activation of ERK 1/2 at the NK immunologic synapse.	[30], [31], [32] [14], [33]
CD8	T-lymphocyte differentiation antigen T8/Leu-2, OKT8 T cell antigen, p32, T cell co-receptor, CD8 alpha.	Prevents activation-induced apoptosis; enhances cytolytic activity; IFN γ production in HIV	[34] [12] [35] [36]
CD11a	Integrin, Alpha L (Antigen CD11a (p180), ITGAL, Lymphocyte Function Associated Antigen 1 (LFA-1), Alpha Polypeptide.	Adhesion and granule polarization; ERK 1/2 activation; co-stimulatory	[37] [33] [38] [39] [40]
CD11b	Integrin, Alpha M, Complement Receptor Type 3, Alpha subunit; CR3A α ; Cell Surface Glycoprotein MAC-1 Subunit Alpha, Leukocyte adhesion receptor Mo1, Cr-3 Alpha chain, MAC1A, SLEB6.	Adhesion and degranulation.	[41] [40, 42] [43] [44, 45]
CD16	Fc Fragment of IgG, Low Affinity IIIa Receptor for (CD16a); FC-gamma RIII-Alpha 3; FCGR3A, IGFR3.	Important in NK cell development and lytic function; mediates ADCC.	[46] [47–49] [13]
CD18	Integrin beta 2, complement component 3 receptor 3 and 4 subunit, Leukocyte Cell adhesion molecule, LFA-1, MAC-1, p150,95	Essential role in target cell binding and NK cell cytotoxicity.	[39–42, 45, 50, 51] [52].
CD27	TNFRSF7 (Tumor Necrosis Factor Receptor Superfamily 7), T14, CD27L Receptor, S152, Tp55	Binds CD70; marker of immature NK; expression regulated by IL-15; immuno-regulatory	[53–55]
CD57	Beta-1,3-glucuronyltransferase 1, GLCATP, GLCUATP, Human natural killer-1 (HNK1), NK1, LEU7	Marker of differentiation, acquired after HCMV infection, potential HCMV memory marker.	[56] [57] [21] [22]
CD94	Killer Cell Lectin-Like Receptor Subfamily D, Member 1, KP43, NK cell receptor.	Pairs with NKG2A or NKG2C and binds HLA-E to form inhibitory or activating complexes, respectively. Monitors MHC-I levels.	[58] [59] [60] [61] [17]
CD117	c-kit, PBT, SCFR (stem cell factor receptor), mast cell growth factor receptor (MCGFR).	Expressed on CD56 ^{bright} NK cell subset, suppresses apoptosis of CD56 ^{bright} NK cells, enhances IL-2 induced proliferation and IFN γ production in CD56 ^{bright} NKs, enhances proliferation in combination with IL-2/IL-15. Genetic disruption of c-kit and c-kit ligand in mice results in a quantitative NK cell deficiency.	[62] [63–65] [20, 66] [67, 68]
CD122	Interleukin-2 receptor beta, IL15RB, High affinity IL-2 receptor subunit beta, IL-2RB, p75, P70-75.	Common signal transducing receptor beta chain for IL-2 and IL-15. Signals through Jak1, Jak 3 and STAT5; NK cell survival.	[69] [70] [71]
CD158a	KIR2DL1/S1, NKAT1 (Natural Killer-associated transcript), MHC Class I NK Cell Receptor	KIR family of inhibitory NK cell receptors, specific for HLA-C2; inhibits NK cell cytotoxic function upon binding HLA-C2 on target cells.	[72] [7]
CD158b	KIR2DL2, NKAT6, MHC Class I NK Cell Receptor	KIR family of inhibitory NK cell receptors, specific for HLA-C1; inhibits NK cell cytotoxic function upon binding HLA-C1 on target cells.	[7, 73]
NKB1 (CD158e1)	NKB1B, KIR3DL1, NKAT-3, HLA-BW4-Specific Inhibitory NK cell receptor, AMB11	KIR family of inhibitory NK cell receptors, specific for HLA-A, HLA-B expressing Bw4 epitope; inhibits NK cell cytotoxic function upon binding HLA-A and -B8 on target cells.	[7, 72–75]
DNAM1 (CD226)	DNAX Accessory Molecule, PTA1, TLISA1, Platelet and T cell activation	Ig superfamily. Binds LFA-1, PVR, and nectin-2, NK cell immune surveillance and tumor cell cytotoxicity, facilitates NK/dendritic cell interaction, involved in	[76] [77] [78] [79] [80] [81–83]

Marker	Aliases	Function in NK cells	References
	antigen, T lineage-specific activation antigen 1 antigen	immune synapse formation and NK cell activation; soluble CD226 can reduce tumor cell growth.	
2B4 (CD244)	Natural Killer Cell Receptor 2B4, NAIL (NK Cell Activation-Inducing Ligand), NKR2B4, SLAMF4, h2B4, Nmrk	SLAM family of receptors, ligand for CD48, stimulates IL-2-activated NK cells; NK activating signals transmitted through CD244/SAP/Fyn pathway; inhibitory signals through CD244/EAT-2.	[84, 85] [86] [8]
NKG2D (CD314)	KLRK-1 (Killer Cell Lectin-Like Receptor Subfamily K, Member), KLR	C-type lectin family, binds MICA/B and ULBPs on target cells, pairs with DAP10; signals through PI3K/Akt and GRB2/VAV1; cytotoxicity	[8] [87–91] [92]
NKp46 (CD335)	Natural Cytotoxicity Triggering Receptor 1 (NCR1), LY94, NK cell Activating Receptor	NK cell activating receptor; Ig-like transmembrane receptor; binds viral hemagglutinin; signals lysis of tumor cells; triggers apoptosis of neutrophils in conjunction with Fas/FasL; no co-activation signal required.	[93] [94] [95] [96]
NKp30 (CD337)	Natural Cytotoxicity Triggering Receptor-3, Lymphocyte Antigen 117, Activating Natural Killer Receptor P30, MALS.	NK cell activating and Ig-like transmembrane receptor, CD28 family member; expressed on resting PB NKs; activation of NKs through ERK1/2; production of IFN γ ; No co- activation signal required; important for NK cell/DC contact.	[38, 95, 96]
Perforin	Perforin 1 PFP (Pore Forming Protein), FLH2, PFN1, Cytolysin,	Contained in cytolytic granules; required for cytotoxicity. Similar mechanism to complement component C9.	[97–99] [23]

* Abbreviations: ADCC - antibody-mediated cellular cytotoxicity; DAP10 – DNAX-activating protein of 10 kDa; DC – dendritic cell; DNAX – tau subunit of DNA polymerase III; ERK – extracellular signal related kinase; EAT-2 Ewing’s sarcoma-activated transcript-2; FHL – familial hemophagocytic lymphohistiocytosis; GRB – growth factor receptor-bound protein; HCMV – human cytomegalovirus; HIV – human immunodeficiency virus; HLA – human leukocyte antigen; JAK – Janus kinase; KIR - killer Immunoglobulin-like receptors; LFA-1 – lymphocyte function associated antigen-1; MHC – major histocompatibility complex; MICA/B – MHC class I chain-related A and B proteins; NKAT- NK associated transcript; NKIS – NK immunologic synapse; PB – peripheral blood; PVR – polio virus receptor; SAP – SLAM-associated protein; SLAM – signaling lymphocyte activation molecule; STAT – signal transducer and activator of transcription.

Table 2

Antibody clones and experimental set up.

Tube number	Antibody 1	Antibody 2	Antibody 3	Antibody 4
1	CD3 PerCP BD 340663 Clone SK7	CD56 Alex Fluor 647 Catalogue # BD 557711 Clone B159	CD158a FITC Catalogue # BD5556062 Clone HP-3E4	NKB1 (CD158e1) PE Catalogue # BD555967 Clone DX9
2	CD3 PerCP	CD56 AF647	CD158b FITC Catalogue # BD559784 Clone CH-L	CD8 PE Catalogue # BD555635 Clone HIT8a
3	CD3 PerCP	CD56 AF647	CD16 FITC Catalogue # BD555406 Clone 3G8	CD16 PE Catalogue # BD347617 Clone B73.1
4	CD3 PerCP	CD56 AF647	CD11a FITC Catalogue # BD555383 Clone HII11	CD2 PE Catalogue # BD555327 Clone RPA2.10
5	CD3 PerCP	CD56 AF647	CD94 FITC Catalogue # BD555888 Clone HP-3D9	Nkp46 (CD335) PE Catalogue # Beckman Coulter im3711 Clone BAB281
6	CD3 PerCP	CD56 AF647	DNAM1 (CD226) FITC Catalogue # BD559788 Clone DX11	NKG2D (CD314) PE Catalogue # R&D#fab139p Clone 149810
7	CD3 PerCP	CD56 AF647	CD11b Biotin Catalogue # BD555387 Clone ICRF44	Nkp30 (CD337) PE Catalogue # R&D#fab1849p Clone 210845
8	CD3 PerCP	CD56 AF647	CD244-FITC Catalogue # BD550815 Clone 2-69	CD27 PE Catalogue # BD555441 Clone M-T271
9	CD3 PerCP	CD56 AF647	CD122 Biotin Catalogue # BD554524 Clone Mik-β3	CD117 PE Catalogue # BD555714 Clone YB5.B8
10	CD3 PerCP	CD56 AF647	CD18 FITC Catalogue # BD 555923 Clone 6.7	CD57 PE Catalogue # BD 560844 Clone NK-1
11	CD3 PerCP	CD56 AF647	Perforin-FITC Catalogue # BD 556577 Clone deltaG9	
Control	CD3 PerCP	CD56 AF647	Mouse IgG – FITC Catalogue # BD 556577	Rat IgG - PE Catalogue # BD 559317
Control	CD3 PerCP	CD56 AF647	Mouse IgG – PerCP Biolegend Catalogue #400250	Mouse IgG - AF647 Catalogue # BD 557783
Streptavidin-conjugated antibody	Alexa Fluor 488- streptavidin Molecular Probes			

Table 3

Percent positive cells and mean fluorescence intensity of all markers in total NK cells, CD56^{bright}, and CD56^{dim} subpopulations.

	Total NK % positive mean +/- S.D. (range)	Total NK MFI mean +/- S.D. (range)	CD56 ^{bright} % positive mean +/- S.D. (range)	CD56 ^{bright} MFI mean +/- S.D. (range)	CD56 ^{dim} % positive mean +/- S.D. (range)	CD56 ^{dim} MFI mean +/- S.D. (range)
CD56⁺, CD3⁺ N=40	6.47 +/- 3.97 (0.61 – 16.87)		8.56 +/- 6.90 (0.63 – 38.32)		90.20 +/- 6.84 (61.68 – 98.29)	
CD2 N=36	72.0 +/- 18.16 (23.1 – 100)	268.03 +/- 177.4 (30.4 – 840)	94.09 +/- 9.24 (66.7 – 100)	692.8 +/- 448.95 (203 – 2325)	69.35 +/- 19.55 (18.5 – 100) N=37	227.59 +/- 153.62 (18.1 – 646)
CD8 N=37	39.33 +/- 16.75 (8.92 – 77.3)	43.01 +/- 58.11 (4.46 – 348)	34.21 +/- 17.29 (0 – 70.8) N=36	24.29 +/- 24.41 (4.02 – 99.7)	38.66 +/- 17.83 (8.85 – 78.2)	42.66 +/- 51.65 (4.07 – 299)
CD11a N=36	90.35 +/- 16.18 (24.6 – 100)	118.78 +/- 66.44 (29.9 – 311) N=37	98.78 +/- 5.02 (75 – 100)	114.16 +/- 70.18 (25.5 – 331)	92.2 +/- 12.5 (50.9 – 100) N=37	118.5 +/- 65.5 (30.1 – 310)
CD11b	80.01 +/- 24.48 (7.1 – 99.4) N=37	70.5 +/- 36.7 (9.22 – 183) N=37	94.76 +/- 15.75 (14.3 – 100) N=31	79.73 +/- 43.06 (18.4 – 230) N=37	79.87 +/- 23.35 (7.14 – 99.4) N=32	65.18 +/- 42.02 (4.16 – 180) N=38
CD16 3G8	48.28 +/- 23.26 (4.8 – 88.7) N=37	81.08 +/- 104.56 (4.85 – 602) N=37	26.32 +/- 20.98 (0 – 100) N=37	34.53 +/- 84.44 (2–519) N=37	54.38 +/- 25.27 (4.2 – 93.7) N=38	85.38 +/- 106.1 (4.04 – 605) N=38
CD16 B73.1	53.68 +/- 21.6 (1.3 – 85.9) N=37	70.02 +/- 56.04 (6.49 – 219)	19.64 +/- 17.82 (0–57.9) N=37	17.04 +/- 22.68 (2.19 – 96.8)	58.12 +/- 23.54 (1.79 – 92) N=38	75.6 +/- 63.05 (3.49 – 227)
CD18	90.89 +/- 13.03 (46.6 – 100) N=22	85.7 +/- 62.39 (21.6 – 265) N=21	92.21 +/- 20.44 (20 – 100) N=23	81.51 +/- 78.15 (6.42 – 287) N=22	90.57 +/- 12.99 (43.2 – 100) N=23	83.58 +/- 61.1 (19.9 – 263) N=22
CD27	14.47 +/- 15.4 (1.8 – 81.8) N=30	10.72 +/- 7.94 (3.33 – 41.4) N=35	33.5 +/- 14.74 (8 – 58.7) N=27	24.96 +/- 21.18 (4.73 – 89) N=32	10.74 +/- 9.73 (0.66 – 46.8) N=31	9.45 +/- 8.12 (3.0 – 43) N=36
CD57	44.9 +/- 19.53 (17.2 – 94.1) N=22	757.7 +/- 493.28 (67.4 – 1738) N=22	19.69 +/- 28.34 (0 – 100) N=23	113.62 +/- 183 (1.84 – 560) N=23	46.09 +/- 19.6 (18.5 – 94.7) N=23	792.0 +/- 538.86 (68.7 – 1876) N=23
CD94	41.85 +/- 17.56 (3.3 – 82.4) N=32	20.59 +/- 15.37 (6.5 – 88) N=37	82.21 +/- 19.38 (50 – 100) N=30	57.12 +/- 29.05 (14.1 – 121) N=34	38.73 +/- 18.64 (8.4 – 82.6) N=33	15.92 +/- 10.47 (5.3 – 64.1) N=38
CD117	6.70 +/- 18.70 (0 – 89.33) N=22	14.38 +/- 32.35 (2.13 – 162) N=27	72.4 +/- 41.98 (0 – 100) N=18	18.04 +/- 28.89 (0 – 107) N=23	5.94 +/- 18.42 (0 – 89.1) N=23	13.22 +/- 32.37 (2.03 – 169) N=28
CD122	76.42 +/- 27.72 (0 – 100) N=30	48.49 +/- 25.78 (3.06 – 126) N=35	76.94 +/- 35.34 (0 – 100) N=29	67.09 +/- 39.2 (0 – 178) N=34	75.85 +/- 27.70 (0 – 99.97) N=31	48.16 +/- 25.78 (3.04 – 124) N=36
CD158a N=37	9.97 +/- 9.73 (0 – 46.86)	7.67 +/- 8.30 (2.9 – 44.5)	4.37 +/- 10.83 (0 – 50)	5.35 +/- 6.76 (0 – 41.8)	11.02 +/- 10.31 (0 – 51.26)	7.94 +/- 8.98 (2.93 – 50.4)
CD158b N=37	24.62 +/- 12.52 (0.34 – 63.4)	13.49 +/- 7.32 (3.39 – 34.1)	9.69 +/- 12.68 (0 – 50)	7.44 +/- 6.02 (0 – 24.3)	26.47 +/- 13.84 (0 – 69)	14.07 +/- 7.72 (3.39 – 36.6)
NKBI (CD158c) N=37	15.70 +/- 10.89 (0 – 37.7)	40.87 +/- 35.65 (1.84 – 163)	7.24 +/- 17.46 (0 – 100)	11.43 +/- 15.90 (0 – 51.7)	17.40 +/- 11.17 (0 – 35.7)	44.51 +/- 39.98 (1.85 – 178)

	Total NK % positive mean +/- S.D. (range)	Total NK MFI mean +/- S.D. (range)	CD56 ^{bright} % positive mean +/- S.D. (range)	CD56 ^{bright} MFI mean +/- S.D. (range)	CD56 ^{dim} % positive mean +/- S.D. (range)	CD56 ^{dim} MFI mean +/- S.D. (range)
DNAMI	33.28 +/- 25.31 (0 - 96) N=37	12.28 +/- 9.38 (4.79 - 52.3) N=37	47.25 +/- 33.53 (0 - 100) N=36	20.52 +/- 39.10 (5.42 - 244) N=36	32.60 +/- 26.22 (0 - 94.7) N=38	10.82 +/- 6.45 (4.71 - 40.3) N=38
2B4	35.06 +/- 27.73 (0.6 - 96.4) N=30	11.20 +/- 6.28 (4.61 - 38) N=35	22.96 +/- 24.44 (0 - 100) N=36	11.4 +/- 11.97 (5.42 - 244) N=36	35.63 +/- 27.29 (2.47 - 97.9) N=31	13.39 +/- 14.42 (4.61 - 89.5) N=36
NKG2D	49.75 +/- 23.80 (0 - 86.92) N=37	19.23 +/- 11.74 (4.89 - 55.3) N=37	73.32 +/- 23.0 (0 - 100) N=36	34.28 +/- 30.95 (8.35 - 195) N=36	47.56 +/- 23.56 (0 - 86.5) N=38	17.48 +/- 10.96 (4.27 - 56.3) N=38
NKp46	43.25 +/- 26.0 (0.8 - 95.5) N=32	22.32 +/- 14.02 (5.6 - 56.8) N=37	76.43 +/- 25.84 (0 - 100) N=31	49.37 +/- 34.34 (0 - 141) N=34	40.5 +/- 26.8 (0 - 97.8) N=33	20.3 +/- 13.45 (4.72 - 55.8) N=38
NKp30	12.28 +/- 16.54 (0 - 84.9) N=31	7.73 +/- 6.34 (1.83 - 24.9) N=36	8.36 +/- 18.49 (0 - 100) N=31	5.61 +/- 7.24 (0 - 116) N=36	12.93 +/- 16.44 (0 - 84.3) N=32	9.48 +/- 10.52 (1.85 - 56.6) N=37
Perforin	61.37 +/- 20.74 (2.0 - 91.6) N=36	39.02 +/- 19.8 (8.94 - 77.0) N=40	16.15 +/- 21.41 (0 - 100) N=35	15.26 +/- 24.56 (0 - 132) N=35	68.34 +/- 19.11 (4.14 - 95) N=35	41.94 +/- 19.78 (13 - 74.4) N=35